Music for Alzheimer's Disease Prevention
(iSTEP+ Trial)
Trial Summary
What is the purpose of this trial?
The goal of this clinical trial is to test the benefits of beat-accented music stimulation (BMS) for behavioral changes of physical activity (PA) in older adults with subjective memory complaints. Specific Aims are to determine (1) whether BMS beneficially influences PA behaviors and psychological responses to PA in older adults for 6 months, and (2) whether exercising with BMS differently influences physical and cognitive functioning as well as quality of life in older adults.To test the effects of BMS on PA, participants will be randomly assigned to an exercise intervention that either includes BMS or does not include BMS. Participants will attend a supervised group strength training (ST) (30 min/day) and and aerobic exercise (AE) (30-50 min/day) session for 3 days/week for the first 2 months, 1 day/week for the next 2 months (while encouraging participants to independently perform both AE and ST on other days), and independently for the final 2 months (always with a goal of performing \>150min/week AE and 3 days/week of ST for 30 min/day).
Do I need to stop taking my current medications to join the trial?
The trial does not specify if you need to stop taking your current medications. However, you cannot participate if you are using medication for Alzheimer's disease or if you've changed the dosage of medications for anxiety or depression in the last 6 months.
What data supports the idea that Music for Alzheimer's Disease Prevention is an effective treatment?
The available research shows mixed results for the effectiveness of Music for Alzheimer's Disease Prevention. One study found that listening to Mozart improved spatial-temporal reasoning in a person with Alzheimer's, suggesting music might help with certain cognitive tasks. Another study noted that music-based interventions could improve quality of life and mood, though they had limited effects on cognition. Additionally, rhythmic auditory stimulation seemed to reduce the burden on caregivers during walking exercises, even if it didn't significantly change walking characteristics. Overall, while music shows some promise, more research is needed to fully understand its benefits compared to other treatments.12345
What safety data exists for music-based treatments for Alzheimer's prevention?
The pilot study on Rhythmic Auditory Stimulation (RAS) with traumatic brain injury patients reported no adverse events, suggesting a favorable safety profile. However, specific safety data for music-based treatments in Alzheimer's prevention is not directly available in the provided research. Further studies are needed to confirm safety in this specific context.678910
Is Beat-accented music stimulation (BMS) a promising treatment for Alzheimer's disease prevention?
Yes, Beat-accented music stimulation (BMS) is a promising treatment for Alzheimer's disease prevention. Research suggests that music can improve memory, mood, and cognitive functions in people with Alzheimer's. Music therapy can enhance quality of life, reduce medication needs, and help with mood and self-expression. It also shows potential in maintaining cognitive abilities and improving mood in dementia patients.345911
Research Team
Kyoung Shin Park, PhD
Principal Investigator
Emory University
Eligibility Criteria
This trial is for older adults with memory complaints who are able to participate in regular physical activity. They should be willing to exercise with or without beat-accented music as part of the study and commit to a structured exercise program for 6 months.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants engage in a supervised group strength training and aerobic exercise program with or without beat-accented music stimulation for 6 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Beat-accented music stimulation (BMS) (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Emory University
Lead Sponsor
Dr. R. Donald Harvey
Emory University
Chief Medical Officer
MD from Emory University School of Medicine
Dr. George Painter
Emory University
Chief Executive Officer since 2013
PhD in Synthetic Organic Chemistry from Emory University
Alzheimer's Association
Collaborator
Dr. Joanne Pike
Alzheimer's Association
Chief Executive Officer since 2023
DrPH in Public Health Leadership from the University of North Carolina at Chapel Hill
Dr. Maria C. Carrillo
Alzheimer's Association
Chief Medical Officer
PhD in Neuroscience
University of North Carolina, Greensboro
Collaborator